Renal impairment trials are typically included as part of the clinical development of a drug. This whitepaper, based on years of experience executing renal trials, provides practical information for pharma and biotech professionals. In this whitepaper, you’ll gain knowledge of:
- Similarities and differences between FDA and EMEA guidance on renal trials.
- Recommended timing for renal trials to optimize Phase II and Phase III trials
- Solutions and guidance for those conducting hepatic trials.